Gene expression in cerebral ischemia: A new approach for neuroprotection

Cerebrovascular Diseases

Volumn 21, Issue SUPPL. 2, 2006, Pages 30-37

  Millán, Mónica ^a   Arenillas, Juan ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Angiogenesis; Apoptosis; Cerebral ischemia; Gene expression; Neuroprotection

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; BETA LACTAM ANTIBIOTIC; CALCIUM CHANNEL BLOCKING AGENT; CEFTRIAXONE; DPH 067517; FIBROBLAST GROWTH FACTOR 2; GLUTAMATE RECEPTOR ANTAGONIST; LACTACYSTIN BETA LACTONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEU DIFFERENTIATION FACTOR; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; PROTEINASE INHIBITOR; RS 100642; SCATTER FACTOR; SCAVENGER; SODIUM CHANNEL BLOCKING AGENT; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

APOPTOSIS; BRAIN ISCHEMIA; CLINICAL TRIAL; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; EXCITOTOXICITY; GENE EXPRESSION; GENE INDUCTION; GENE THERAPY; HUMAN; INFLAMMATION; NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANGIOGENIC PROTEINS; ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BRAIN; BRAIN ISCHEMIA; CALCIUM; CEREBRAL REVASCULARIZATION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR CIRCULATION; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID TRANSPORTER 2; GENE EXPRESSION REGULATION; GENE THERAPY; GLUTAMIC ACID; HUMANS; NEUROPROTECTIVE AGENTS; SODIUM-CALCIUM EXCHANGER; STROKE; TRANSCRIPTIONAL ACTIVATION;

EID: 33646484956     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091701     Document Type: Review

References (55)

1. Hachinski V: Stroke: the next 30 years. Stroke 2002;33:1-4.
2. King HC, Sinha AA: Gene expression profile analysis by DNA microarrays. JAMA 2001;286:2280-2288.
3. Read SJ, Parsons AA, Harrison DC, Philpott K, Kabnick K, O'Brien S, et al: Stroke genomics: approaches to identify, validate, and understand ischemic stroke gene expression. J Cereb Blood Flow Metab 2001;21:755-778.
4. Pulsinelli W: Pathophysiology of acute ischemic stroke. Lancet 1992;339:533-536.
5. Akins PT, Liu PK, Hsu CY: Immediate early gene expression in response to cerebral ischemia: friend or foe? Stroke 1996;27:1682-1687.
6. Ginsberg MD: Adventures in the pathophysiology of brain ischemia: penumbra, gene expression, neuroprotection. The 2002 Thomas Willis Lecture. Stroke 2003;34:214-223.
7. Slevin M, Krupinski J, Kumar P, Gaffney J, Kumar S: Gene activation and protein expression following ischaemic stroke: strategies towards neuroprotection. J Cell Mol Med 2005;9:85-102.
8. May Lu XC, Williams AJ, Yao C, Berti R, Hartings JA, Whipple R, et al: Microarray analysis of acute and delayed gene expression profile in rats after focal ischemic brain injury and reperfusion. J Neurosci Res 2004;77:843-857.
9. Hong H, Liu GC: Current status and perspectives on the development of neuroprotectants for ischemic vascular disease. Drugs Today (Barc) 2003:39:213-222.
10. Heiss WD, Graf R: The ischemic penumbra. Curr Opin Neurol 1994;7:11-19.
11. Ginsberg MD: Injury mechanisms in the ischemic penumbra. Approaches to neuroprotection in acute ischemic stroke. Cerebrovasc Dis 1997;7(suppl 2):7-12.
12. Legos JJ, Tuma RF, Barone FC: Pharmacological interventions for stroke: failures and future. Expert Opin Invest Drugs 2002;11:603-614.
13. Rossi DJ, Oshima T, Atwell D: Glutamate release in severe brain ischemia is mainly by reserved uptake. Nature 2000;403:316-321.
14. 2+ exchanger gene expression in the ischemic core, periinfarct area, an intact brain regions. J Cereb Blood Flow Metab 2005 (Epub ahead of print).
15. Schwartz-Bloom RD, Sah R: Gamma-aminobutyric acid A neurotransmission and cerebral ischemia. J Neurochem 2001;77:353-371.
16. Castillo J, Rodríguez I: Biochemical changes and inflammatory response as markers of brain ischaemia: molecular markers of diagnostic utility and prognosis in human practice. Cerebrovasc Dis 2004;17:7-18.
17. Vallet P, Charnay Y, Steger K, Ogier-Denis E, Kovari E, Herrmann F, et al: Neuronal expression of the NADPH oxidase NOX4, and its regulation in mouse experimental brain ischemia. Neuroscience 2005;132:233-238.
18. Castillo J, Rama R, Dávalos A: Nitric oxide-related brain damage in acute ischemic stroke. Stroke 2000;31:852-857.
19. Ikonomidou C, Turski L: Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? Lancet Neurol 2002;i:383-386.
20. Yao C, Williams AJ, Lu XC, Price RA, Cunningham BS, Berti R, et al: The sodium channel blocker RS100642 reverses down-regulation of the sodium channel α-subunit Na(v) 1.1 expression caused by transient ischemic brain injury in rats. Neurotox Res 2003;5:245-254.
21. Yasuda H, Shichinohe H, Kuroda S, Ishikawa T, Iwasaki Y: Neuroprotective effect of a heat shock protein inducer, geranylgeranylacetone, in permanent focal cerebral ischemia. Brain Res 2005;1032:176-182.
22. Rothstein JD, Pastel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, et al: Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005;433:73-77.
23. Vila N, Castillo J, Dávalos A, Chamorro A: Proinflammatory cytokines and early stroke progression. Stroke 2000;31:2325-2329.
24. Iadecola C, Alexander M: Cerebral ischemia and inflammation. Curr Opin Neurol 2001;14:89-94.
25. Danton GH, Dietrich WD: Inflammatory mechanisms after ischemia and stroke. J Neuropath Exp Neurol 2003;62:127-136.
26. Takagi Y, Harada J, Chiarugi A, Moskowitz MA: STAT1 is activated in neurons after ischaemia and contributes to ischaemic brain injury. J Cereb Blood Flow Metab 2002;22:1311-1318.
27. Castellanos M, Leira R, Serena J, Pumar JM, Lizasoain I, Castillo J, et al: Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003;34:40-46.
28. Montaner J, Alvarez-Sabín J, Molina CA, Anglés A, Abilleira S, Arenillas JF, et al: Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001;32:1759-1766.
29. Berti R, Williams AJ, Velarde LC, Moffett JR, Elliot PJ, Adams J, et al: Effect of the proteasome inhibitor MLN519 on the expression of inflammatory molecules following middle cerebral artery occlusion and reperfusion in rat. Neurotox Res 2002;5:505-514.
30. Vemuganti R, Dempsey RJ, Bowen KK: Inhibition of intercellular adhesion molecule-1 protein expression by antisense oligonucleotides is neuroprotective after transient middle cerebral artery occlusion in rat. Stroke 2004;35:179-184.
31. Wang X, Feuerstein GZ, Xu L, Wang H, Schumacher WA, Ogletree ML: Inhibition of tumor necrosis factor-α-converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol Pharmacol 2004;65:890-896.
32. Choi DW: Excitotoxicity, apoptosis and ischemic stroke. J Biochem Mol Biol 2001;34:8-14.
33. MacManus JP, Linnik MD: Gene expression induced by cerebral ischemia: an apoptotic perspective. J Cereb Blood Flow Metab 1997;17:815-852.
34. Ferrer I, Planas AM: Signaling of cell death and cell survival following focal cerebral ischaemia: life and death struggle in the penumbra. J Neuropath Exp Neurol 2003;62:329-339.
35. Sedarous M, Keramaris E, O'Hare M: Calpains mediate p53 activation and neuronal death evoked by DNA damage. J Biol Chem 2003;278:26031-26038.
36. Harper SJ, LoGrasso P: Signalling for survival and death in neurones. The role of the stress-activated kinases, JNK and p38. Cell Signal 2001;13:299-310.
37. Guan QH, Pei DS, Zhang QG, Hao ZB, Xu TL, Zhang GY: The neuroprotective action of SP600125, a new inhibitor of JNK, on transient brain ischemia/reperfusion-induced neuronal death in rat hippocampal CA1 via nuclear and non-nuclear pathways. Brain Res 2005;1035:51-59.
38. Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, et al: In vivo delivery of a Bcl-xl fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci 2002;22:5423-5431.
39. Krupinski J, Ferrer I, Barrachina M, Secades JJ, Mercadal J, Lozano R: CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase artery occlusion in the rat. Neuropharmacology 2002;42:846-854.
40. Culmsee C, Gerling N, Lehmnan M, Nikolova-Karakashian M, Prehn JHM, Mattson MP, et al: Nerve growth factor survival signalling in cultured hippocampal neurons is mediated through TRKA and requires the common neurotrophin receptor p75. Neuroscience 2002;115:1089-1108.
41. Fujiwara K, Date I, Shingo T, Yoshida H, Kobayashi K, Takeuchi A, et al: Reduction of infarct volume and apoptosis by grafting of encapsulated basic fibroblast growth factor-secreting cells in a model of middle cerebral artery occlusion in rats. J Neurosurg 2003;99:1053-1062.
42. Ijichi A, Sakuma S, Tofilon PJ. Hypoxia-induced vascular endothelial growth factor expression in normal rat astrocyte cultures. Glia 1995;14:87-93.
43. Krupinski J, Kaluza J, Kumar P: Role of angiogenesis in patients with cerebral ischaemic stroke. Stroke 1994;25:1794-1798.
44. Krupinski J, Stroemer P, Slevin M: Three-dimensional structure of newly-formed blood vessels after focal cerebral ischemia in rat. Neuroreport 2003;14:1171-1176.
45. Croll SD, Wiegand SJ: Vascular growth factors in cerebral ischemia. Mol Neurobiol 2001;23:121-135.
46. Sun Y, Jin K, Xie L, et al: VEGF-induced neuroprotection, neurogenesis and angiogenesis after focal cerebral ischaemia. J Clin Invest 2003;111:1843-1851.
47. Sun FY, Guo X: Molecular and cellular mechanisms of neuroprotection by vascular endothelial growth factor. J Neurosci Res 2005;79:180-184.
48. Ay H, Ay I, Koroshetz WJ, et al.: Potential usefulness of basic fibroblast growth factor as a treatment for stroke. Cerebrovasc Dis 2000;9:131-135.
49. Watanabe T, Okuda Y, Nonoguchi N, Zhao MZ, Kajimoto Y, Furutama D, et al: Postischemic intraventricular administration of FGF-2 expressing adenoviral vectors improves neurologic outcome and reduces infarct volume after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2004;24:1205-1213.
50. Shimamura M, Sato N, Oshima K, et al: Novel therapeutic strategy to treat brain ischaemia: overexpression of hepatocyte growth factor gene reduced ischaemic injury without cerebral edema in rat model. Circulation 2004;109:424-431.
51. Xu Z, Ford GD, Croslan DR, Jiang J, Gates A, Allen R, et al: Neuroprotection by neuroregulin-1 following focal stroke is associated with the attenuation of ischemia-induced pro-inflammatory and stress gene expression. Neurobiol Dis 2005;19:461-470.
52. Heistad DD, Faraci F: Gene therapy for cerebrovascular disease. Stroke 1996;27:1688-1693.
53. Sapolsky RM, Steinberg GK: Gene therapy using viral vectors for acute neurologic insults. Neurology 1999;53:1922-1931.
54. Vila N: A genetic approach to ischemic stroke therapy. Cerebrovasc Dis 2004;17(suppl 1): 63-69.
55. Ooboshi H, Ibayashi S, Takada J, Yao H, Kitazono T, Fujishima M: Adenovirus-mediated gene transfer to ischemic brain. Stroke 2001;32:1043-1047.